Combined therapy of mixed dyslipidemia in patients with high cardiovaskular risk and changes in tne lipid target values and atherogenic index of plasma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F14%3A00061277" target="_blank" >RIV/00159816:_____/14:00061277 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.crvasa.2014.01.003" target="_blank" >http://dx.doi.org/10.1016/j.crvasa.2014.01.003</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2014.01.003" target="_blank" >10.1016/j.crvasa.2014.01.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Combined therapy of mixed dyslipidemia in patients with high cardiovaskular risk and changes in tne lipid target values and atherogenic index of plasma

Popis výsledku v původním jazyce

Purpose: To evaluate the safety and efficacy of combined lipid-modifying agents (statin + fenofibrate) on plasma lipid profile including the atherogenic index of plasma (AIP = log [TG/HDL-C]) in patients at high and very high cardiovascular (CV) risk andmixed dyslipi-demia. Method: A total of 81 patients (53 males, 28 females; 60 +- 9.8 years) were included. Mixed dyslipidemia was defined as having 2 of the following 3 lipid abnormalities: LDL-cholesterol (C) >2.5 mmol/l, HDL-C <1.0 mmol/l in males and<1.3 mmol/l in females, triglycerides (TG) >1.7 mmol/l. Global CV risk was estimated according to the current European guidelines. Management with fenofibrate (160-267 mg) + atorvastatin (10-20 mg) or simvastatin (20- 40 mg) was indicated for 6 months.Males and females were stratified according to the AIP risk categories: AIP <0.11 (low risk), AIP >0.21 (high risk). Results: About 3/4 of high or very high CV risk patients with mixed dyslipidemia (n = 81) suffer from impaired glucose me

Název v anglickém jazyce

Combined therapy of mixed dyslipidemia in patients with high cardiovaskular risk and changes in tne lipid target values and atherogenic index of plasma

Popis výsledku anglicky

Purpose: To evaluate the safety and efficacy of combined lipid-modifying agents (statin + fenofibrate) on plasma lipid profile including the atherogenic index of plasma (AIP = log [TG/HDL-C]) in patients at high and very high cardiovascular (CV) risk andmixed dyslipi-demia. Method: A total of 81 patients (53 males, 28 females; 60 +- 9.8 years) were included. Mixed dyslipidemia was defined as having 2 of the following 3 lipid abnormalities: LDL-cholesterol (C) >2.5 mmol/l, HDL-C <1.0 mmol/l in males and<1.3 mmol/l in females, triglycerides (TG) >1.7 mmol/l. Global CV risk was estimated according to the current European guidelines. Management with fenofibrate (160-267 mg) + atorvastatin (10-20 mg) or simvastatin (20- 40 mg) was indicated for 6 months.Males and females were stratified according to the AIP risk categories: AIP <0.11 (low risk), AIP >0.21 (high risk). Results: About 3/4 of high or very high CV risk patients with mixed dyslipidemia (n = 81) suffer from impaired glucose me

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

56

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

"e133"-"e139"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—